$30.35
Insights on Dentsply International Inc.
Revenue is up for the last 2 quarters, 947.0M → 1.01B (in $), with an average increase of 6.4% per quarter
Netprofit is up for the last 2 quarters, -266.0M → 67.0M (in $), with an average increase of 497.0% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 26.5% return, outperforming this stock by 52.3%
In the last 3 years, Intuitive Surgical, Inc. has given 29.3% return, outperforming this stock by 83.5%
0.77%
Downside
Day's Volatility :2.07%
Upside
1.3%
14.96%
Downside
52 Weeks Volatility :38.3%
Upside
27.44%
Period | Dentsply International Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -13.09% | 0.5% | 0.0% |
6 Months | -1.08% | 11.7% | 0.0% |
1 Year | -25.85% | 6.2% | 2.2% |
3 Years | -54.23% | 13.5% | -23.0% |
Market Capitalization | 6.4B |
Book Value | $15.89 |
Dividend Share | 0.56 |
Dividend Yield | 2.07% |
Earnings Per Share (EPS) | -0.62 |
PEG Ratio | 1.53 |
Wall Street Target Price | 37.04 |
Profit Margin | -3.33% |
Operating Margin TTM | 7.02% |
Return On Assets TTM | 2.41% |
Return On Equity TTM | -3.72% |
Revenue TTM | 4.0B |
Revenue Per Share TTM | 18.7 |
Quarterly Revenue Growth YOY | 3.0% |
Gross Profit TTM | 2.1B |
EBITDA | 632.0M |
Diluted Eps TTM | -0.62 |
Quarterly Earnings Growth YOY | 0.18 |
EPS Estimate Current Year | 2.06 |
EPS Estimate Next Year | 2.41 |
EPS Estimate Current Quarter | 0.43 |
EPS Estimate Next Quarter | 0.46 |
What analysts predicted
Upside of 22.04%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 4.0B | ↓ 0.18% |
Net Income | -1.0B | ↓ 35.73% |
Net Profit Margin | -25.36% | ↑ 14.03% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.0B | ↑ 1.08% |
Net Income | 262.9M | ↓ 126.0% |
Net Profit Margin | 6.52% | ↑ 31.88% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.3B | ↓ 17.06% |
Net Income | -83.0M | ↓ 131.57% |
Net Profit Margin | -2.48% | ↓ 9.0% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 4.3B | ↑ 27.2% |
Net Income | 411.0M | ↓ 595.18% |
Net Profit Margin | 9.67% | ↑ 12.15% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.9B | ↓ 7.74% |
Net Income | -950.0M | ↓ 331.14% |
Net Profit Margin | -24.22% | ↓ 33.89% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 4.0B | ↑ 1.1% |
Net Income | -132.0M | ↓ 86.11% |
Net Profit Margin | -3.33% | ↑ 20.89% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 965.0M | ↓ 5.67% |
Net Income | 69.0M | ↓ 5.48% |
Net Profit Margin | 7.15% | ↑ 0.01% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 983.0M | ↑ 1.87% |
Net Income | -15.0M | ↓ 121.74% |
Net Profit Margin | -1.53% | ↓ 8.68% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 978.0M | ↓ 0.51% |
Net Income | -23.0M | ↑ 53.33% |
Net Profit Margin | -2.35% | ↓ 0.82% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↑ 5.11% |
Net Income | 86.0M | ↓ 473.91% |
Net Profit Margin | 8.37% | ↑ 10.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 947.0M | ↓ 7.88% |
Net Income | -266.0M | ↓ 409.3% |
Net Profit Margin | -28.09% | ↓ 36.46% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↑ 6.86% |
Net Income | 67.0M | ↓ 125.19% |
Net Profit Margin | 6.62% | ↑ 34.71% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 8.7B | ↓ 16.31% |
Total Liabilities | 3.6B | ↓ 4.94% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 8.6B | ↓ 0.97% |
Total Liabilities | 3.5B | ↓ 1.29% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 9.3B | ↑ 8.59% |
Total Liabilities | 4.4B | ↑ 24.63% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 9.2B | ↓ 1.31% |
Total Liabilities | 4.2B | ↓ 4.46% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 7.6B | ↓ 17.1% |
Total Liabilities | 3.8B | ↓ 8.28% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 7.4B | ↓ 3.57% |
Total Liabilities | 4.1B | ↑ 6.4% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 9.2B | ↑ 2.37% |
Total Liabilities | 4.3B | ↑ 3.5% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 7.6B | ↓ 16.56% |
Total Liabilities | 3.8B | ↓ 9.94% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.7B | ↑ 0.39% |
Total Liabilities | 4.0B | ↑ 5.32% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.7B | ↓ 0.3% |
Total Liabilities | 3.9B | ↓ 2.16% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.2B | ↓ 5.87% |
Total Liabilities | 3.8B | ↓ 2.99% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.4B | ↑ 2.35% |
Total Liabilities | 4.1B | ↑ 6.42% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 499.8M | ↓ 16.96% |
Investing Cash Flow | -253.3M | ↓ 11.56% |
Financing Cash Flow | -249.8M | ↓ 37.67% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 632.8M | ↑ 26.61% |
Investing Cash Flow | -68.4M | ↓ 73.0% |
Financing Cash Flow | -466.1M | ↑ 86.59% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 635.0M | ↑ 0.35% |
Investing Cash Flow | -1.1B | ↑ 1516.96% |
Financing Cash Flow | 490.0M | ↓ 205.13% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 657.0M | ↑ 3.46% |
Investing Cash Flow | -358.0M | ↓ 67.63% |
Financing Cash Flow | -379.0M | ↓ 177.35% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 517.0M | ↓ 21.31% |
Investing Cash Flow | -138.0M | ↓ 61.45% |
Financing Cash Flow | -329.0M | ↓ 13.19% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 93.0M | ↓ 46.24% |
Investing Cash Flow | -40.0M | ↑ 0.0% |
Financing Cash Flow | -10.0M | ↓ 93.42% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 142.0M | ↑ 52.69% |
Investing Cash Flow | -29.0M | ↓ 27.5% |
Financing Cash Flow | -161.0M | ↑ 1510.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -21.0M | ↓ 114.79% |
Investing Cash Flow | -37.0M | ↑ 27.59% |
Financing Cash Flow | 17.0M | ↓ 110.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 104.0M | ↓ 595.24% |
Investing Cash Flow | -29.0M | ↓ 21.62% |
Financing Cash Flow | -87.0M | ↓ 611.76% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 134.0M | ↑ 28.85% |
Investing Cash Flow | -2.0M | ↓ 93.1% |
Financing Cash Flow | -109.0M | ↑ 25.29% |
Sell
Neutral
Buy
Dentsply International Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Dentsply International Inc. | -6.62% | -1.08% | -25.85% | -54.23% | -40.37% |
Intuitive Surgical, Inc. | -6.16% | 43.78% | 26.5% | 29.27% | 115.63% |
Resmed Inc. | -5.54% | 32.21% | -18.09% | -13.03% | 76.47% |
Becton, Dickinson And Company | -4.71% | -9.32% | -10.84% | -10.48% | -3.21% |
West Pharmaceutical Services Inc | -5.16% | 12.48% | 3.07% | 14.2% | 197.69% |
Alcon Ag | -4.59% | 13.21% | 10.42% | 3.56% | 35.65% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Dentsply International Inc. | 22.28 | NA | 1.53 | 2.06 | -0.04 | 0.02 | 0.02 | 15.89 |
Intuitive Surgical, Inc. | 67.57 | 67.57 | 7.13 | 6.28 | 0.16 | 0.08 | NA | 39.37 |
Resmed Inc. | 30.5 | 30.5 | 1.75 | 7.4 | 0.22 | 0.11 | 0.01 | 30.47 |
Becton, Dickinson And Company | 53.75 | 53.75 | 1.34 | 12.95 | 0.05 | 0.03 | 0.02 | 87.68 |
West Pharmaceutical Services Inc | 49.52 | 49.52 | 6.72 | 7.62 | 0.21 | 0.12 | 0.0 | 39.2 |
Alcon Ag | 39.92 | 39.92 | 4.59 | 3.06 | 0.05 | 0.02 | 0.0 | 41.81 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Dentsply International Inc. | Buy | $6.4B | -40.37% | 22.28 | -3.33% |
Intuitive Surgical, Inc. | Buy | $133.0B | 115.63% | 67.57 | 27.16% |
Resmed Inc. | Buy | $27.1B | 76.47% | 30.5 | 19.77% |
Becton, Dickinson And Company | Buy | $67.6B | -3.21% | 53.75 | 6.44% |
West Pharmaceutical Services Inc | Buy | $28.6B | 197.69% | 49.52 | 20.12% |
Alcon Ag | Buy | $38.7B | 35.65% | 39.92 | 10.3% |
Vanguard Group Inc
BlackRock Inc
Artisan Partners Limited Partnership
Mariner Value Strategies, LLC
Arnhold & S. Bleichroeder Advisers, LLC
State Street Corporation
In the quarter ending March,2024. Dentsply International Inc. has declared dividend of $0.16
Read Morea global total solutions provider dentsply sirona is the world’s largest manufacturer of professional dental products and technologies, empowering dental professionals to provide better, safer and faster dental care. our products and solutions include leading positions and platforms across consumables, equipment, technology, and specialty products. dentsply sirona is one global team that brings out the best in our people, lives and breathes high performance and personal accountability, acts with uncompromising integrity, improves the practice of dentistry with an unrelenting commitment to our customers and demonstrates a passion for innovation that shapes the dental industry. as the dental solutions company™, dentsply sirona provides dental professionals a comprehensive end-to-end solutions offering. this offering includes some of the best-known and established brands in the industry. we develop, manufacture and market a complete line of dental and oral health products, including gener
Organization | Dentsply International Inc. |
Employees | 15000 |
CEO | Mr. Simon D. Campion |
Industry | Health Technology |
Cerevel Therapeutics Holdings Inc
$30.35
-1.84%
Vaxcyte Inc
$30.35
-1.84%
Janux Therapeutics Inc
$30.35
-1.84%
Spdr Nuveen S&p High Yield Municipal Bond Etf
$30.35
-1.84%
Radnet Inc
$30.35
-1.84%
The St. Joe Co
$30.35
-1.84%
Harley-davidson, Inc.
$30.35
-1.84%
Vaneck Vectors Fallen Angel Hiyld Bd Etf
$30.35
-1.84%
Aurora Innovation Inc
$30.35
-1.84%